Bionano Genomics (BNGO) Total Current Liabilities (2017 - 2026)

Bionano Genomics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 19.62% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $21.2 million (down 19.62% YoY), while the FY2025 annual figure was $22.9 million, down 38.57% from the prior year.
• Total Current Liabilities came in at $21.2 million for Q1 2026 at Bionano Genomics, down from $22.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $100.0 million in Q4 2023 to a low of $18.7 million in Q1 2022.
• A 5-year average of $36.0 million and a median of $33.5 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 178.75% in 2023 and plunged 62.67% in 2024, its largest moves.
• Bionano Genomics' Total Current Liabilities stood at $35.9 million in 2022, then jumped by 178.75% to $100.0 million in 2023, then slumped by 62.67% to $37.3 million in 2024, then tumbled by 38.57% to $22.9 million in 2025, then decreased by 7.47% to $21.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $21.2 million, $22.9 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison